CA2372912C - Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique - Google Patents

Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique Download PDF

Info

Publication number
CA2372912C
CA2372912C CA002372912A CA2372912A CA2372912C CA 2372912 C CA2372912 C CA 2372912C CA 002372912 A CA002372912 A CA 002372912A CA 2372912 A CA2372912 A CA 2372912A CA 2372912 C CA2372912 C CA 2372912C
Authority
CA
Canada
Prior art keywords
cancer
neoplasia
alkylamino
benzenesulfonamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002372912A
Other languages
English (en)
Other versions
CA2372912A1 (fr
Inventor
Karen Seibert
Jaime Masferrer
Gary B. Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Priority claimed from CA002267186A external-priority patent/CA2267186C/fr
Publication of CA2372912A1 publication Critical patent/CA2372912A1/fr
Application granted granted Critical
Publication of CA2372912C publication Critical patent/CA2372912C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002372912A 1997-10-14 1997-10-14 Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique Expired - Fee Related CA2372912C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002267186A CA2267186C (fr) 1996-10-15 1997-10-14 Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002267186A Division CA2267186C (fr) 1996-10-15 1997-10-14 Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique

Publications (2)

Publication Number Publication Date
CA2372912A1 CA2372912A1 (fr) 1998-04-23
CA2372912C true CA2372912C (fr) 2008-12-02

Family

ID=4163412

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002372912A Expired - Fee Related CA2372912C (fr) 1997-10-14 1997-10-14 Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique

Country Status (1)

Country Link
CA (1) CA2372912C (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
WO2005048942A2 (fr) * 2003-11-13 2005-06-02 Pharmacia Corporation Polytherapie contenant un inhibiteur cox-2 et un agent antineoplasique
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.

Also Published As

Publication number Publication date
CA2372912A1 (fr) 1998-04-23

Similar Documents

Publication Publication Date Title
CA2267186C (fr) Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique
US6469040B2 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
WO1998016227A9 (fr) Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique
US6025353A (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
CA2270469C (fr) Procede d'utilisation d'inhibiteurs de cyclo-oxygenase-2 comme agents anti-angiogeniques
CA2372912C (fr) Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique
NZ517374A (en) Method of using cycloozygenase-2 inhibitors to prevent a neoplasia that produces a prostaglandin
IL154502A (en) Use of cyclooxygenase-2 inhibitors in the preparation of medicaments for treating angiogenesis-related disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141014